Enterprise Value
-33.27M
Cash
71.38M
Avg Qtr Burn
-8.049M
Short % of Float
0.29%
Insider Ownership
6.10%
Institutional Own.
29.52%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tegoprubart (AT-1501) Details Amyotrophic lateral sclerosis | Phase 2 Update | |
Tegoprubart (AT-1501) Details Renal Transplantation | Phase 2 Update | |
Tegoprubart (AT-1501) Details Type 1 diabetes, Islet Cell Transplantation | Failed Discontinued | |
Tegoprubart (AT-1501) Details Autoimmune nephritis | Failed Discontinued | |
Tegoprubart (AT-1501) Details IgA nephropathy | Failed Discontinued |